Shattuck Labs Advanced SL-325 Clinical Trial Plans

The company has initiated plans for a Phase 2 study targeting the inflammatory skin disease hidradenitis suppurativa.

Updated on Oct. 1, 2026 in Healthcare

Shattuck Labs Advanced SL-325 Clinical Trial Plans

Live Poll

Do you trust pharmaceutical companies to prioritize patient health over corporate profit when developing new drugs?

Shattuck Labs has announced the upcoming RECEPTIVE-HS1 Phase 2 clinical trial to evaluate SL-325 in patients with moderate to severe hidradenitis suppurativa. The company also appointed industry veteran Shoba Ravichandran as its new Senior Vice President of Clinical Development.

Why it matters

Hidradenitis suppurativa is an inflammatory condition linked to high DR3 expression in lesions, making it a critical area for targeted therapy development. This trial seeks to address significant patient needs by investigating the efficacy of SL-325 in reducing abscesses and nodules.

The RECEPTIVE-HS1 trial will enroll 150 patients over a 16-week, double-blind, placebo-controlled treatment period. Existing cash reserves are expected to fund the company's operational activities through 2029.

The players

Shattuck Labs

A biotechnology company based in Austin, Texas, and Durham, North Carolina, focused on the development of therapeutic proteins for cancer and inflammatory diseases.

Shoba Ravichandran

The newly appointed Senior Vice President of Clinical Development who brings over 20 years of experience in drug development to the company.

The details

The trial requires participants to have at least five abscesses and inflammatory nodules to be eligible for treatment with either low-dose or high-dose SL-325. The study tracks the proportion of patients achieving HiSCR50 at the 16-week mark, with an extension phase continuing through week 52.

The IND submission for the trial is scheduled for October 2026.
The RECEPTIVE-HS1 trial is expected to initiate in 2026.
Clinical primary and secondary endpoint assessments occur at week 16.
The trial extension period concludes at week 52.
Top-line data from the treatment period are expected in the first half of 2028.

Market Landscape

This move positions Shattuck Labs within the competitive landscape of autoimmune and inflammatory disease treatments. The focus on DR3 expression signals a strategic effort to capture market share in dermatology-related inflammatory disorders.

While the trial is in its early stages, patients with hidradenitis suppurativa may eventually gain access to new treatment options if the clinical study proves successful. Financial stakeholders should note that current company cash projections support operations well into 2029.

The takeaway

Clinical trial milestones like the initiation of RECEPTIVE-HS1 provide important benchmarks for companies developing targeted therapies. Investors and patients should monitor the projected data disclosure in 2028 as a key indicator of the drug's therapeutic potential.